MannKind | 销售和管理费用



Selling And Administration Expenses 更改 日
Adma Biologics USD 24.59M 5.01M 2024-12
Dynavax Technologies USD 41.58M 1.48M 2024-12
Eli Lilly USD 2.42B 324.7M 2024-12
Halozyme Therapeutics USD 42.25M 1.01M 2024-12
Insmed USD 142.51M 23.58M 2024-12
MacroGenics USD 27.81M 13.71M 2024-12
MannKind USD 23.97M 56K 2024-12
Merck USD 2.53B 319M 2025-03
Novo Nordisk DKK 16.59B 501M 2024-09
Pfizer USD 4.27B 1.06B 2024-12
Sanofi EUR 2.22B 980M 2025-03
Xencor USD 14.92M 148K 2024-12



MannKind 销售和管理费用 - 当前值，历史数据，预测，统计，图表和经济日历 - Apr 2025.